The global atopic dermatitis drugs market generated ~US$ 2.2 Bn in revenue in 2018, and is expected to expand at a CAGR of ~27% during the forecast period.
Exponential Growth of Biologic Drugs Favor Market Growth
According to a study published by BioMed Central, U.K – an electronic-only medical journal, it was found that, on a global level, ~15 – 20% children and ~1 – 3% adults suffer from atopic dermatitis (AD). The growing prevalence of this disease has triggered the demand for efficacious drugs in the atopic dermatitis drugs market.
Biologic drugs are projected for exponential growth during the forecast period. In 2018, biologic drugs accounted for the highest market share of ~42%, and continue to dominate the market share with a projected value of ~77% in 2027. Thus, it is evident that, healthcare companies in the atopic dermatitis drugs market are increasing research & development activities to improve the efficacy of biologic drugs in order to provide instant relief for patients.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111932
Since atopic dermatitis has a high risk of recurrence, healthcare companies in the atopic dermatitis drugs market are identifying drugs that improve the functioning of the immune system by helping to fight off bacteria and viruses. For instance, in August 2019, Sanofi – a French multinational pharmaceutical company, announced the approval of Dupixent® (dupilumab) – a biologic drug to treat moderate-to-severe atopic dermatitis, by the European Commission.
Topical PDE4 Inhibitor Drugs Emerge as Non-steroid-based Option
Healthcare companies in the atopic dermatitis drugs market are developing new drug agents to expand the treatment options for the disease. They are developing new moisturizers that confer skin-barrier protection, biologics, and lipid-replenishing topical drugs. Manufacturers are making these treatment options available at retail and hospital pharmacies.
After several clinical trials, healthcare companies are introducing efficacious ointments that provide result-oriented outcome in patients. In 2027, PDE4 inhibitor (Phosphodiesterase Type 4 inhibitor) drugs will hold the second-highest revenue after biologic drugs in the atopic dermatitis drugs market. On that account, healthcare companies are propelling the use of nonsteroidal topical ointments that prevent the release of cyclic adenosine monophosphate (cAMP), which is one of the major causes that aggravates atopic dermatitis.
Get a glimpse of the in-depth analysis through our Report Brochure
Stakeholders in the atopic dermatitis drugs market are gaining the faith of patients, as nonsteroidal topical ointments are considered safer and better than topical corticosteroids, especially for younger patients. Due to the high prevalence of atopic dermatitis in children, healthcare providers in the atopic dermatitis drugs landscape are observing a shift in consumer preference, as caregivers are hesitant to opt for steroid-based options.
Experimental Biologics Reduce Side Effects of Atopic Dermatitis Drugs
Although topical treatment drugs are projected for growth in the atopic dermatitis drugs market, in many cases, these treatments have been ineffective in many patients. As a result, patients are advised to opt for traditional immunosuppressant medications such as cyclosporin (CYA) and methotrexate (MTX). These immunosuppressants show effectiveness in AD, but their routine use is demonstrated with incompetent disease responses and other adverse effects in patients. Also, there is a risk of renal, hepatic, and other toxicities in body organs that adversely affect the healing period of these treatment options.
Thereupon, healthcare companies are approaching experimental biologics to prevent the toxicity and improve the efficacy of atopic dermatitis drugs. They should focus on preventing skin inflammation and flares while minimizing the side effects of these drugs.
Analysts’ Viewpoint on Atopic Dermatitis Drugs Market
Although the trend of online pharmacies is gaining momentum in the atopic dermatitis drugs market, caregivers and patients have more faith in retail pharmacies. This is expected to manifest during the forecast period, as the retail pharmacies sector will grow from ~US$ 1.3 billion in 2018 to ~US$ 15.3 billion by 2027. However, the side effects of certain classes of atopic dermatitis drugs is one of the major challenges for stakeholders in the supply chain. On that account, market players should opt for a multidimensional approach, and educate parents and healthcare providers regarding the availability of pharmacological therapies. Also, healthcare companies should develop new drug agents in biologics that gain FDA (Food and Drug Administration) approval.
View full report@ https://qyresearchmedical.com/report/atopic-dermatitis-drugs-market-drug-class-corticosteroids-pde4-inhibitors-biologics-skin-barrier-emollients-cni-immunosuppressants-others-distribution-channel-hospital-pharmacies-retail-pharmacies-online-019-2030/111932
Atopic Dermatitis Drugs Market: Overview
The global atopic dermatitis drugs market for the historical period of 2017 and forecast period of 2019 to 2027, rise in investments toward research & development and novel pipeline drugs are projected to boost the growth of the global atopic dermatitis drugs market during the forecast period.
Novel Pipeline Drugs and Rise in Incidence Rate of Atopic Dermatitis: Key Drivers
Dermatological disorders differ across the globe, based on geographic location, climatic conditions, socioeconomic status, lifestyles, age, gender, heredity, and personal habits.
According to the World Health Organization (WHO), over 900 million people were affected with skin diseases in 2017, and five common skin disorders, which include atopic dermatitis, accounted for around 80% of the skin disorders.
The high prevalence and substantial rise in incidence rate of atopic dermatitis across the globe is the key factor driving the atopic dermatitis drugs market. Atopic dermatitis, a common and chronic inflammatory skin disease, affects 15% to 20% children and 1% to 3% adults across the world, every year.
Leading pharmaceutical companies strive to address these unmet medical needs through new product developments.
AbbVie Inc. is planning to launch Upadacitinib, which is a JAK inhibitor, by 2021, for the treatment of atopic dermatitis. Currently, phase 2 clinical data in atopic dermatitis supports advancement toward phase 3.
New approvals and commercialization of novel therapeutic drugs under clinical trial studies are projected to drive the global atopic dermatitis drug market during the forecast period.
Biologics Drug Class Leads Market
The biologics segment dominated the global atopic dermatitis drugs market in 2018, and is expected to account for a major market share during the forecast period, owing to an increase in the preference of patients for biologics, since they are effective. Anticipated launches and adoption of biologic drugs between 2019 and 2022 is a key trend that is expected to propel the biologics segment during the forecast period.
The PDE4 inhibitors segment in the global atopic dermatitis drugs market is projected to expand at significant CAGR during the forecast period. Rise in the prevalence of eczema is a driving factor that is expected to propel the segment during the forecast period.
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111932/2900
Atopic dermatitis is one of the most common types of eczema. It is a chronic, inflammatory skin disorder, with a prevalence as high as 20% in children and 1% to 3% in adults.
North America to Dominate Global Atopic Dermatitis Drugs Market
North America accounted for a major share of the global atopic dermatitis drugs market in 2018, followed by Europe. Early adoption of biologics, favorable healthcare reimbursement policies in the U.S. and Canada, and rapid increase in market penetration of new players with novel therapeutic drugs are likely to drive the atopic dermatitis drugs market in North America.
Europe was also an attractive market for atopic dermatitis drugs in 2018. Economic revival in the European Union has resulted in enhanced healthcare expenditure, and hence, increased adoption of biologics and PD34 inhibitors in the healthcare industry in the region is likely to drive the market. Further, well-established healthcare facilities, new product approvals, and commercialization and favorable medical reimbursement policies are anticipated to drive the market in the region.
The atopic dermatitis drugs market in Asia Pacific is estimated to grow at a faster pace than other regions during the forecast period, due to increase in the focus on the development of healthcare infrastructure by public as well as private hospitals, along with rise in the demand for novel therapeutics among a significant patient population. Additionally, wide scope of development and rapid urbanization offer significant opportunities to emerging as well as established players in the region. This, in turn, drives the market in Asia Pacific.
Global Atopic Dermatitis Drugs Market: Competitive Landscape
Detailed profiles of the manufacturers of atopic dermatitis drugs have been provided in the report to evaluate their key product offerings, financials, business strategies, and recent developments.
Key players operating in the global atopic dermatitis drugs market include
- Mylan N.V.
- Pfizer, Inc.
- LEO Pharma A/S
- Novartis AG
- Bausch Health
- Teva Pharmaceutical Industries Ltd.
Key Questions Answered in TMR’s Atopic Dermatitis Drugs Market Study
- What is the scope of growth of atopic dermatitis drug companies in the pharmaceutical drugs sector?
- What is the estimated Y-o-Y growth of the market from 2019 to 2027?
- What is the influence of the changing trends in technologies on the market?
- Is North America likely to continue to remain the most profitable regional market for atopic dermatitis drug providers?
- Which factors are expected to hamper the market during the forecast period?
- Which are the leading companies in the global market?
Segmentation of the Atopic Dermatitis Drugs Market
- PDE4 Inhibitors
- Skin Barrier Emollients
- CNI Immunosuppressants
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
TABLE OF CONTENT
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Atopic Dermatitis Drugs Market
4. Market Overview
4.3. Market Dynamics
4.4. Global Atopic Dermatitis Drugs Market Analysis and Forecasts, 2017–2027
5. Market Outlook
5.1. Disease Epidemiology
5.2. Pipeline Analysis
5.3. Recent Development
6. Global Atopic Dermatitis Drugs Market Analysis and Forecasts, by Drug Class
6.1. Introduction & Definition
6.2. Market Value Forecast by Drug Class, 2017–2027
6.2.2. PDE4 Inhibitors
6.2.4. Skin Barrier Emollients
6.2.5. CNI Immunosuppressants
6.3. Market Attractiveness by Drug Class
7. Global Atopic Dermatitis Drugs Market Analysis and Forecasts, by Distribution Channel
7.1. Introduction & Definition
7.2. Market Value Forecast by Distribution Channel, 2017–2027
7.2.1. Hospital Pharmacies
7.2.2. Retail Pharmacies
7.2.3. Online Pharmacies
7.3. Market Attractiveness by Distribution Channel
8. Global Atopic Dermatitis Drugs Market Analysis and Forecasts, by Region
8.1. Key Findings
8.2. Market Value Forecast by Region
8.2.1. North America
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness by Country/Region
9. North America Atopic Dermatitis Drugs Market Analysis and Forecast
9.2. Market Value Forecast by Drug Class, 2017–2027
9.2.2. PDE4 Inhibitors
9.2.4. Skin Barrier Emollients
9.2.5. CNI Immunosuppressants
9.3. Market Value Forecast by Distribution Channel, 2017–2027
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Value Forecast by Country, 2017–2027
9.5. Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Atopic Dermatitis Drugs Market Analysis and Forecast
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111932/2900
You can place an order or ask any questions, please feel free to contact email@example.com | +1 9197 992 333
QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.
For Latest Update Follow Us: